KN5505

KN5505 is a chimeric antigen receptor-engineered natural killer (CAR-NK) cell therapy currently in the early preclinical research stage. Developed by Rui Therapeutics (Shenzhen Enrui Kainuo Biotechnology Co., Ltd.), it is part of a broader pipeline of CAR-NK candidates utilizing the company's proprietary technology platforms. The therapy is designed to leverage the innate cytotoxic potential of natural killer cells, which are genetically modified to express a chimeric antigen receptor (CAR) for the targeted elimination of specific cells. While Rui Therapeutics classifies KN5505 as a "First-in-Class" candidate, the specific molecular target and the primary disease indication have not yet been publicly disclosed.